Isocitrate dehydrogenase 1 and 2 mutations, 2‐hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia
Andrew M. Brunner(Harvard University), Amir Fathi(Massachusetts General Hospital), Hua Yang(China Pharmaceutical University), Seth A. Wander(Harvard University), Meghan Burke(Harvard University), Hossein Sadrzadeh(Boston University), Karen K. Ballen(University of Virginia Health System), Kimberly Straley(Agios Pharmaceuticals (United States)), Ilene Galinsky(Dana-Farber Cancer Institute), Katharine Yen(Agios Pharmaceuticals (United States)), A. John Iafrate(Massachusetts General Hospital), Sophia Adamia(Beth Israel Deaconess Medical Center), Timothy A. Graubert(Massachusetts General Hospital), Christine Connolly(Massachusetts General Hospital), Sam Agresta(Agios Pharmaceuticals (United States)), Gabriela Hobbs(Massachusetts General Hospital), Richard M. Stone(Dana-Farber Cancer Institute), Ashley Perry(Harvard University), Eyal C. Attar(Memorial Sloan Kettering Cancer Center), Aura Y. Ramos(Harvard University), Darrell R. Borger(Massachusetts Eye and Ear Infirmary), Yi‐Bin Chen(Massachusetts General Hospital), Donna Neuberg(Otsuka (Japan)), Christelle Joseph(Harvard University), Philip C. Amrein(Massachusetts General Hospital)
Cited by 33
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
|Nature Biotechnology|2014|2.3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k